% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Gobits:307660,
author = {R. Gobits and N. Schleußner$^*$ and G. R. Oliver and M.
Rutenberg Schoenberg and A. M. de Jesus Domingues and P.
Ramkumar and S. W. F. Suen and M. P. M. Koomen and F.
Paolucci and K. Martens and A. Guiseris Martinez$^*$ and J.
Volk$^*$ and C. Artmann$^*$ and M. Mastel$^*$ and K.
Ouyang$^*$ and M. Kloor and E. D. Bankaitis and H. E. Stoub
and J. Puschhof$^*$ and K. Brown and S. Pretzer and D. A.
Nelson and E. Struminger and A. Zessin and A. Brown and C.
Evans and D. Yetsko and M. Harrington and G. Salg and M.
Schneider and T. Schmidt and E. Helman and D. Plenker and C.
Barnett and R. T. Jones and B. C. Köhler$^*$ and E.
Driehuis and R.-F. Jackstadt$^*$},
title = {{F}unctional {P}recision {M}edicine {U}sing
{M}icro{O}rgano{S}pheres for {T}reatment {R}esponse
{P}rediction in {A}dvanced {C}olorectal {C}ancer.},
journal = {JCO precision oncology},
volume = {10},
number = {10},
issn = {2473-4284},
address = {Alexandria, VA},
publisher = {American Society of Clinical Oncology},
reportid = {DKFZ-2026-00117},
pages = {e2500501},
year = {2026},
note = {DKFZ-ZMBH Alliance / #NCTZFB26# / #DKTKZFB26# /
#EA:A013#LA:A013#},
abstract = {Neoadjuvant chemotherapy is a key component of curative
treatment in advanced colorectal cancer (CRC). However,
$30\%-40\%$ of patients show progression on treatment,
underscoring the need for predictive tools to guide up-front
treatment selection. Scalable and reproducible methods for
patient stratification remain limited. MicroOrganoSpheres
(MOS) are droplet-encapsulated 3D tumor models that allow
for high-throughput functional drug testing. Here, we
evaluate the potential of tumor-derived MOS to predict
response to chemotherapy in patients with CRC.MOS droplets
were generated from 37 primary and/or metastatic tumor
samples collected from 21 patients. MOS response to
chemotherapy was quantified using AI-based imaging analysis
and compared with clinical response (RECIST/disease-free
survival [DFS]) and lesion-specific outcomes (pathologic
response/percent tumor volume change).MOS chemoprediction
assay showed high reproducibility (coefficients of variation
≤ $2.5\%).$ MOS drug sensitivity recapitulated patient
response with $83\%$ accuracy in the full sample cohort and
$100\%$ accuracy when derived from primary tumors. Patients
with sensitive MOS showed longer DFS. Individual MOS
analysis revealed preservation of intratumor heterogeneity
in vitro and enabled identification of drug-resistant
clones.MOS technology offers a scalable and robust
functional precision medicine platform with potential to
guide clinical decision making in CRC. The platform
accurately predicts patient response to chemotherapy and
provides insights into intrapatient and intratumor
heterogeneity.},
keywords = {Humans / Colorectal Neoplasms: drug therapy / Colorectal
Neoplasms: pathology / Precision Medicine: methods / Male /
Female / Middle Aged / Aged / Neoadjuvant Therapy /
Treatment Outcome},
cin = {A013 / D300 / HD01 / HD02},
ddc = {610},
cid = {I:(DE-He78)A013-20160331 / I:(DE-He78)D300-20160331 /
I:(DE-He78)HD01-20160331 / I:(DE-He78)HD02-20160331},
pnm = {311 - Zellbiologie und Tumorbiologie (POF4-311)},
pid = {G:(DE-HGF)POF4-311},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:41538757},
doi = {10.1200/PO-25-00501},
url = {https://inrepo02.dkfz.de/record/307660},
}